Home » Stocks » Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. (COLL)

Stock Price: $18.33 USD 0.57 (3.21%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 629.38M
Revenue (ttm) 301.71M
Net Income (ttm) 198,000
Shares Out 34.34M
EPS (ttm) 0.00
PE Ratio n/a
Forward PE 4.55
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $18.33
Previous Close $17.76
Change ($) 0.57
Change (%) 3.21%
Day's Open 17.56
Day's Range 17.43 - 18.47
Day's Volume 575,049
52-Week Range 10.12 - 25.59

More Stats

Market Cap 629.38M
Enterprise Value 767.91M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 34.34M
Float 30.02M
EPS (basic) n/a
EPS (diluted) 0.00
FCF / Share -9.11
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.68M
Short Ratio 11.40
Short % of Float 14.77%
Beta 1.05
PE Ratio n/a
Forward PE 4.55
P/FCF Ratio n/a
PS Ratio 2.09
PB Ratio 3.95
Revenue 301.71M
Operating Income 12.86M
Net Income 198,000
Free Cash Flow -313.22M
Net Cash -138.53M
Net Cash / Share -4.03
Gross Margin 34.15%
Operating Margin 4.26%
Profit Margin 0.10%
FCF Margin -103.81%
ROA 1.70%
ROE 0.16%
ROIC 26.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 8
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$27.38*
(49.37% upside)
Low
8.00
Current: $18.33
High
35.00
Target: 27.38
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue29728028.481.71---
Revenue Growth5.81%884.73%1564.29%----
Gross Profit10311525.881.50---
Operating Income-23.75-20.69-75.45-94.08-26.91-17.67-16.04
Net Income-22.72-39.13-74.87-94.18-27.26-17.92-16.20
Shares Outstanding33.4532.9530.2724.2613.540.931.70
Earnings Per Share-0.68-1.19-2.47-3.88-1.48-22.72-4.06
Operating Cash Flow27.78169-67.02-75.05-21.57-17.95-16.53
Capital Expenditures-6.44-5.48-0.99-0.48-0.36-0.01-0.21
Free Cash Flow21.35164-68.01-75.53-21.93-17.96-16.74
Cash & Equivalents17014711915395.791.717.63
Total Debt21.5911.501.484.156.8113.071.03
Net Cash / Debt14813511714988.98-11.356.60
Assets30629113616297.725.099.03
Liabilities21920031.4927.1112.6517.333.45
Book Value87.4391.5910413585.07-89.35-68.23
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Collegium Pharmaceutical, Inc.
Country United States
Employees 255
CEO Joseph J. Ciaffoni

Stock Information

Ticker Symbol COLL
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: COLL
IPO Date May 7, 2015

Description

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting. The company offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. Furhter, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.